Oncology Medical News about Prostatic Neoplasms GnRH-agonist Histrelin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Relationships between FSH, inhibin B, anti-Mullerian hormone and testosterone during long-term treatment with the GnRH-agonist Histrelin in patients with prostate cancer
European Journal of Endocrinology, 10/30/09

Eldar–Geva T et al. – The secondary increase in FSH following initial suppression with the implant is probably related to impaired inhibin B secretion. The lack of inhibin B response to the secondary increase in FSH suggests that long–term exposure of Sertoli–cells to GnRH–agonist impairs their function. This effect appears to be selective since unlike inhibin B, AMH increased. In the absence of testosterone, FSH has a role in AMH regulation.

<< Previous
Successful outcome after resection of liver metastasis arising...

Next >>
Management of patients with pregnancy-associated gastric cancer...